본문으로 건너뛰기
← 뒤로

Clinical Characteristics and Risk Factors of Immune Checkpoint Inhibitor-Related Myocarditis: A Real World Observational Study.

1/5 보강
Clinical cardiology 2026 Vol.49(4) p. e70312
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
8199 patients, 1638 (19.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Routine cardiac surveillance is needed in high-risk patients receiving ICI therapy. [TRIAL REGISTRATION] Registered at https://www.chictr.org.cn (identifier: ChiCTR2300075974).

Zhan M, Long Q, Liu R, Huang L, Wu B, Xu T, He J

📝 환자 설명용 한 줄

[BACKGROUND] Rare occurrence, immune checkpoint inhibitors (ICI)-related myocarditis are poorly documented in the literature.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value p = 0.021
  • p-value p < 0.001
  • 95% CI 1.132-4.440
  • OR 1.391

이 논문을 인용하기

↓ .bib ↓ .ris
APA Zhan M, Long Q, et al. (2026). Clinical Characteristics and Risk Factors of Immune Checkpoint Inhibitor-Related Myocarditis: A Real World Observational Study.. Clinical cardiology, 49(4), e70312. https://doi.org/10.1002/clc.70312
MLA Zhan M, et al.. "Clinical Characteristics and Risk Factors of Immune Checkpoint Inhibitor-Related Myocarditis: A Real World Observational Study.." Clinical cardiology, vol. 49, no. 4, 2026, pp. e70312.
PMID 42007771
DOI 10.1002/clc.70312

Abstract

[BACKGROUND] Rare occurrence, immune checkpoint inhibitors (ICI)-related myocarditis are poorly documented in the literature.

[RESEARCH DESIGN AND METHODS] We conducted a retrospective review of patients who had ICI until June 2023. Patient follow-up was extended until death or on May 2024. The primary outcome was the incidence of suspected ICI-related myocarditis. Logistic regression was used to investigate the associations between clinical characteristics and suspected ICI-related myocarditis.

[RESULTS] Among the included 8199 patients, 1638 (19.98%) patients developed suspected ICI-related myocarditis. Logistic regression revealed that thymomas and thymic carcinomas (OR 2.242; [95% CI, 1.132-4.440], p = 0.021), lung cancer (OR 1.259; [95% CI, 1.119-1.416], p < 0.001), older patients (OR 1.021; [95% CI, 1.016-1.026], p < 0.001), male (OR 1.213; [95% CI, 1.061-1.388], p = 0.005), block two or more immune checkpoints (OR = 1.391 [95% CI 1.058-1.828], p = 0.018), combined with hypertension (OR = 1.326 [95% CI 1.162-1.513], p < 0.001), or hyperlipidemia (OR = 1.656 [95% CI 1.302-2.107], p < 0.001) were associated with higher risk of suspected ICI-related myocarditis.

[CONCLUSIONS] This large, real-world cohort demonstrates that the incidence of suspected ICI-related myocarditis may be underestimated in previous literature. Routine cardiac surveillance is needed in high-risk patients receiving ICI therapy.

[TRIAL REGISTRATION] Registered at https://www.chictr.org.cn (identifier: ChiCTR2300075974).

🏷️ 키워드 / MeSH

같은 제1저자의 인용 많은 논문 (5)

🟢 PMC 전문 열기